Recent studies indicate that tumor suppressor genes can be epigenetically silenced through promoter hypermethylation. To further understand epigenetic alterations in cholangiocarcinoma, we have studied the methylation profiles of 12 candidate tumor suppressor genes (APC, E-cadherin/CDH1, MGMT, RASSF1A, GSTP, RAR-b, p14 ARF , p15
Cholangiocarcinoma is an uncommon but highly aggressive malignancy, which arises from the biliary ductal epithelium, either intrahepatically or extrahepatically. There is evidence that the neoplastic transformation of biliary epithelial cells and malignant progression of cholangiocarcinoma is accompanied by a number of genetic and epigenetic alterations. 1, 2 Genetic alterations such as point mutations of K-ras and p53 have been found in a subset of cholangiocarcinoma. [3] [4] [5] [6] Mutation or deletion of p14 ARF and p16 INK4a were not frequent events in cholangiocarcinoma. 7, 8 Although overexpression of b-catenin was frequently encountered in cholangiocarcinoma, mutation of b-catenin has not been identified to date. 9 These studies indicate that genetic alterations frequently seen in other epithelial cancers are not commonly seen in cholangiocarcinoma.
Recent studies have shown that the function of a tumor suppressor gene can be silenced through promoter methylation. Epigenetic inactivation of a set of tumor suppressor genes through promoter methylation had been recently studied in intrahepatic cholangiocarcinoma in Asian populations. 2 However, to our knowledge, methylation profiles of extrahepatic cholangiocarcinoma has not been well characterized. To further understand the epigenetic changes in cholangiocarcinoma and to see the difference in epigenetic alterations between intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma, we have studied the promoter methylation profiles of 12 candidate tumor suppressor genes in 72 cases of cholangiocarcinoma, including 36 cases of intrahepatic cholangiocarcinoma and 36 cases of extrahepatic cholangiocarcinoma and compared to 10 cases of benign biliary epithelia. In all, 12 tumor suppressor genes, involved in several signal transductional pathways, are adenomatous polyposis coli (APC), E-cadherin/CDH1, O 
Materials and methods

Tumor Samples
In all, 72 cases of cholangiocarcinoma, including 36 cases of intrahepatic cholangiocarcinoma and 36 cases of extrahepatic cholangiocarcinoma, were collected from Johns Hopkins Pathology and Cytopathology Archives, with the permission of Johns Hopkins University Institutional Review Board. The specimens include 52 cases of paraffin-embedded surgical resection specimens and 20 cases of cytologic smears from fine-needle aspiration biopsies. All the cytologic cases had confirmed diagnosis from subsequent tumor biopsies or resections. In all, 10 cases of negative bile duct surgical margins were used as control. No initial chemotherapy or radiation therapy was instituted before tumor excision or fineneedle aspiration and biopsy procedure. The tissue was fixed either in buffered-formalin for surgical specimens or in ethanol-based fixative for fine-needle aspiration and biopsy specimens. Consecutive sections were cut at 4 mm from paraffin-embedded tissue blocks and mounted for histopathologic evaluation using conventional hematoxylin and eosin (H&E) staining. H&E-stained sections also served as a guide for DNA analysis. For DNA extraction, consecutive 10 mm sections from resected specimens were directly collected into sterile Eppendorff tubes. Cells from cytologic smears were scraped into Eppendorff tubes by sterile surgical blades. Genomic DNA was isolated by digestion with 100 mg/ml proteinase K and followed by conventional phenol/chloroform (1:1) extraction and ethanol precipitation.
Bisulfite Modification and Methylation-Specific PCR
Bisulfite modification and methylation-specific PCR were conducted based on the principle that bisulfite treatment of DNA converts unmethylated cytosine residues into uracil, whereas methylated cytosine residues remain unmodified. Thus, after bisulfite conversion, methylated and unmethylated DNA sequences can be distinguished by sequence-specific primers. DNA was treated with sodium bisulfite as previously described. 10 Briefly, 1 mg of genomic DNA was denatured by incubation with 0.2 M NaOH for 10 min at 371C. Aliquots of 10 mM hydroquinone (30 ml; Sigma Chemical Co., St Louis, MO, USA) and 3 M sodium bisulfite (pH 5.0, 520 ml; Sigma Chemical Co.) were added and the solution was incubated at 501C for 16 h. Treated DNA was purified by use of Wizard DNA purification System (Promega Corp., Madison, WI, USA), desulfonated with 0.3 M NaOH, precipitated with ethanol, and resuspended in water. Modified DNA was stored at À701C until used. DNA sequences containing promoter regions of APC, E-cadherin/CDH1, RASSF1A, GSTP, RAR-b, p14 ARF , p15
INK4b
, p16
INK4a
, p73, MGMT, hMHL1 and DAPK genes were first amplified in a single PCR run with 30 cycles using flanking primer sets as previously described.
11,12 DNA methylation of CpG islands was then determined by PCR using specific primers for both methylated and unmethylated DNA. 11, 12 Two sets of primers were used to amplify each region of interest: one pair recognized a sequence in which CpG sites are unmethylated (bisulfite modified to UpG), and the other recognized a sequence in which CpG sites are methylated (unmodified by bisulfite treatment). Negative control samples without DNA template (water only) and DNA were included for each set of PCR. PCR products were analyzed on 1% polyacrylamide gels. Methylation status of hMHL-1 gene was analyzed only in 52 cases of surgical specimens; however not in cytologic specimens, due to the limitation of samples in the latter. Methylation-specific PCR of all the cases with negative methylation status and some of the methylationpositive cases were repeated to confirm the results. 
Statistical Analysis
Results
Frequency of Tumor Suppressor Gene Promoter Methylation in Cholangiocarcinoma
Promoter methylation profiles of 12 tumor suppressor gene from 72 cases of cholangiocarcinoma and 10 cases of benign biliary epithelia is illustrated in Figure 1 . The frequency of methylation of individual tumor suppressor gene is summarized in ARF and p73 (Fisher's exact test, P ¼ 0.012, 0.017, 0.020, 0.020, 0.026 and 0.026, respectively). There were marginal differences between cholangiocarcinoma and benign biliary epithelium in methylation of MGMT and E-cadherin/CDH1 (P ¼ 0.056 and 0.078, respectively).
Concurrent Methylation of Multiple Tumor Suppressor Genes in Cholangiocarcinoma
Promoter methylation of multiple tumor suppressor genes was frequently seen in cholangiocarcinoma. Number of tumor suppressor genes methylated ranged from one to nine genes in cholangiocarcinoma. Although methylation of single tumor suppressor gene was seen in 50% (5/10) of cases of benign biliary epithelia, it was only encountered in two cases (3%) of cholangiocarcinoma. Of 72 cases of cholangiocarcinoma, 59 cases (82%) had methylation of two or more tumor suppressor genes ( Table 2) . In contrast, methylation of two or more tumor suppressor gene promoters was not seen in benign biliary tissue ( Figure 1 ). Furthermore, 50 cases (70%) of cholangiocarcinoma had methylation of three or more tumor suppressor genes and 37 cases (52%) of cholangiocarcinoma had methylation of four or more tumor suppressor genes ( Table 2) . Methylation of multiple tumor suppressor genes tends to occur in those most frequently methylated genes, such as RASSF1, APC, p15
INK4b and p16 INK4a . For instance, concurrent methylation of four or more tumor suppressor gene was seen in about 66% (31/47) cases of cholangiocarcinoma that harbored RASSF1A methylation; however, was found only in 32% (8/25) of cases without RASSF1A methylation. The difference between these two groups was statistically significant (P ¼ 0.028). Similarly, there was also a close correlation between methylation of hMLH1 promoter and concurrent methylation of multiple tumor suppressor genes in cholangiocarcinoma. Of 52 cases of cholangiocarcinoma analyzed for hMLH1, methylation of the hMLH1 promoter was found in 25% (13/52) cases. Among hMLH1 methylators, methylation of five or more tumor suppressor genes was seen in 92% (12/13) cases. In contrast, only 39% (15/39) cases without hMLH1 methylation had methylation of five or more tumor suppressor genes (P ¼ 0.001, Table 3 ).
Association between Methylation of Various Genes in Cholangiocarcinoma
To see whether epigenetic inactivation of a restricted number of pathways or of numerous signaling pathways involved in development of cholangiocarcinoma, we analyzed the strength of bivariate association between pairs of tumor suppressor genes methylated in cholangiocarcinoma using Pearson's correlation coefficients. Overall, methylation of all 12 tumor suppressor genes, except DAPK, showed some degree of association with each other. In all, 20 pairs of tumor suppressor genes were identified with significant correlation (Po0.01). Among these 20 pairs, 16 pairs associated with methylation of three core genes: RASSF1A, p16
INK4a and hMLH1 ( Figure 2 ). Not only was methylation of these three tumor suppressor genes correlated each other, but also methylation of each of these three tumor suppressor genes (RASSF1A, p16
INK4a and hMLH1) correlated significantly (Po0.01) with methylation of other tumor suppressor genes (Figure 2a) . Specifically, methylation of RASSF1A promoter was closely associated with the methylation of GSTP, hMLH1, p14
INK4a and p73. Methylation of p16
INK4a promoter was significantly associated with the methylation of APC, E-cadherin/CDH1, hMLH1, p14 ARF , p15, p73, RAR-b and RASSF1A. Whereas methylation of hMLH1 promoter was strongly associated with the methylation of MGMT, p14
INK4a , RAR-b and RASSF1A (Figure 2a ).
Methylation Profiles between Intrahepatic Cholangiocarcinoma and Extrahepatic Cholangiocarcinoma
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Methylation profiles in cholangiocarcinoma B Yang et al frequency, methylation of RASSF1A was seen more frequently in extrahepatic cholangiocarcinoma (30/ 36) than that in intrahepatic cholangiocarcinoma (17/36) (83 vs 47%, P ¼ 0.003). Although methylation of p14 ARF , p73, MGMT and hMLH1 was seen more often in extrahepatic cholangiocarcinoma than intrahepatic cholangiocarcinoma, the difference was not statistically significant (P40.05). On the other hand, methylation of GSTP promoter was more common in intrahepatic cholangiocarcinoma than in extrahepatic cholangiocarcinoma and this difference was statistically significant (31 vs 6%, P ¼ 0.012). Although there was no significant difference in concurrent methylation of multiple tumor suppressor genes between intrahepatic and extrahepatic cholangiocarcinoma (Table 2) , different bivariate association of pairs of tumor suppressor genes exists between intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma (Figure 2b and c) . For example, methylation of GSTP or MGMT was not associated with methylation of other tumor suppressor genes in intrahepatic cholangiocarcinoma (Figure 2b (Figure 2c ).
Correlation of Tumor Suppressor Gene Methylation and Clinicopathologic Data
Methylation profiles have been correlated with clinicopathologic data, such as patient gender, tumor size and tumor differentiation. There was no significant difference in the frequency of tumor suppressor gene methylation between genders (50 males and 22 females, P40.05). The tumor size of cholangiocarcinoma ranged from 1.0 to 13 cm. Tumor differentiation of 52 cases of surgical specimens was graded histopathologically into well-, moderately-and poorly differentiated. For intrahepatic cholangiocarcinoma cases, 26 cases include eight cases of well differentiated, 12 cases of moderately differentiated and six cases of poorly differentiated. For extrahepatic cholangiocarcinoma, 26 cases consist of 13 cases of well differentiated, nine cases of moderately differentiated and four cases of poorly differentiated. All the cases of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma are classified as adenocarcinoma, not otherwise specified. There was no statistical significance between the frequency of individual tumor suppressor gene methylation and the degree of tumor differentiation (P40.05, data not shown). In terms of concerted multiple tumor suppressor gene methylation, methylation of four and more tumor suppression gene promoters was seen relatively more frequently in poorly differentiated tumors (70%, 7/10) than moderately differentiated (47%, 10/21) and well-differentiated tumors (38%, 8/21). However, differences were not statistically significant between poorly-and moderately differentiated (P ¼ 0.28) and between poorly-and welldifferentiated (P ¼ 0.15). 
Discussion
The molecular mechanisms of cholangiocarcinoma are largely unknown. Aberrant methylation of promoter CpG islands associated with human tumor suppressor genes has been studied as an alternative mechanism of gene inactivation that contributes to the biology of several human neoplasms. 13, 14 Although epigenetic changes of intrahepatic cholangiocarcinoma had been recently studied in Asian populations, 2 methylation profiles of extrahepatic cholangiocarcinoma has not been reported to our knowledge. To further understand the epigenetic alterations in cholangiocarcinoma and to compare the methylation profiles between intrahepatic and extrahepatic cholangiocarcinoma, we have studied the methylation status of the promoter CpG islands of 12 tumor suppressor genes in 72 cases of cholangiocarcinoma, including 36 cases of intrahepatic cholangiocarcinoma and 36 cases of extrahepatic cholangiocarcinoma.
Our study demonstrates that epigenetic alteration of tumor suppressor genes, namely promoter hypermethylation, is a frequent event in cholangiocarcinoma. About 85% of cholangiocarcinoma had methylation of at least one tumor suppressor gene that we studied. Although methylation of each of 12 tumor suppressor gene promoters was seen in cholangiocarcinoma, the most frequently methylated tumor suppressor genes were RASSF1A (65%), p15
INK4b (50%), p16 INK4a (50%), APC (46%) and E-cadherin/CDH1 (43%). One of the important findings from our study is that cholangiocarcinoma often had concurrent methylation of multiple tumor suppressor genes. Almost all methylated cases, except two, had methylation of two or more tumor suppressor genes. More than two-thirds of cholangiocarcinomas harbored methylation of three or more tumor suppressor gene promoters and more than half of the cases have methylation of four or more tumor suppressor gene promoters. It appears that development of cholangiocarcinoma may result from disruption of multiple signaling transduction pathways, such as the ras pathway (RASSF1A), Wnt pathway (APC and E-cadherin/CDH1), RB pathway (p16 INK4a ), cell cycle control (p15 INK4b ), p53 pathway (p14 ARF and p73) and microsatellite stability (hMLH1). Our data further indicate that accumulation of such epigenetic alterations through concerted methylation of multiple tumor suppressor genes is required during carcinogenesis of the biliary epithelium.
As 12 tumor suppressor genes examined here represents important elements of several signaling pathways, we are interested to see whether epigenetic inactivation of these tumor suppressor genes reflects disruption of either restricted or numerous signaling pathways involved in the development of cholangiocarcinoma and whether there are linkages between different pathways. Through the analysis of the strength of bivariate association between pairs of tumor suppressor genes methylated in cholangiocarcinoma, we found 20 pairs of tumor suppressor genes with significant correlation coefficients (Po0.01). Interestingly, 16 out of 20 pairs of such association are strongly correlated with the methylation of three core tumor suppressor genes: RASS1A, p16 and hMLH1, which are involved in three separate signaling pathways (ras pathway, pRb pathway and DNA mismatch repair pathway). Our data suggest that these three signaling pathways are likely the main targets epigenetically altered during the development of cholangiocarcinoma.
The human ras association domain family RASSF1A gene was cloned from the lung tumor suppressor locus 3p21.3. 15 It has been shown that the expression of RASSF1A can be silenced through promoter methylation. Indeed, epigenetic inactivation is probably the main method that inactivates RASSF1A in cancer cells, since mutation of RASSF1A is extremely rare in cancer cells. 16 Methylation of RASSF1A has been found in lung, breast, ovarian, renal cell, bladder and gastric carcinomas. [17] [18] [19] [20] [21] [22] We found that the vast majority cases of cholangiocarcinoma had methylation of RASSF1A promoter. Methylation of RASSF1A is often associated with concurrent methylation of multiple other tumor suppressor genes. The latter implies that methylation of RASSF1A may be one of the early events during biliary epithelial carcinogenesis. Although the biologic function of RASSF1A is still not entirely clear, recent studies indicate that RASSF1A is an important effector in mediating rasinduced apoptosis. [23] [24] [25] [26] It has been long speculated that the ras pathway is one of the major targets altered during biliary epithelial carcinogenesis. Previous genetic studies have shown that activation of the ras oncogene through point mutations presented in a subset of cholangiocarcinoma, particularly in perihilar cholangiocarcinoma. 4, 27 Our study further suggests that disruption of the ras pathway through the methylation of CpG islands in the RASSF1A promoter may also contribute to the development of cholangiocarcinoma. Recent studies indicate that methylation of RASSF1A and ras mutations are mutually exclusive in colorectal cancers. 28 Whether such phenomenon exists in cholangiocarcinoma needs further investigation.
Recent studies have indicated that the Wnt pathway is also involved in the pathogenesis of cholangiocarcinoma. Immunohistochemical study has shown that altered expression of b-catenin is found in up to 84% of cholangiocarcinoma. 9 However, mutation of b-catenin was not yet identified by sequencing 58 cases of cholangiocarcinoma. 9 Reduced expression of E-cadherin/CDH1 was also reported in cholangiocarcinoma. 29 We found that about 69% of cases of cholangiocarcinoma had methylation of either APC or E-cadherin/CDH1 or both, including 46% of cholangiocarcinoma with methylation of APC and 43% cases with methylation of E-cadherin/CDH1. Our data suggest that promoter methylation of APC and/or E-cadherin/ CDH1 may contribute in certain extent to the disruption of Wnt pathway and perhaps the activation of b-catenin in cholangiocarcinoma. Interestingly, methylation of APC and E-cadherin/CDH1 seems to be mutually exclusive in majority of cholangiocarcinoma. Approximately two-third of cases of cholangiocarcinoma had methylation of either APC or E-cadherin/CDH1; however, not both. A similar phenomenon was also observed in p53 pathway. We found that 68% of the cases had methylation of either p14 ARF or p73. Our data suggest that disruption of one important element in the same signaling pathway is probably enough to diminish the function of the signaling pathway. According to Knudson's two-hit theory in cancer cells, it will be particularly interesting to see whether correlation between genetical loss of heterozygosity of one allele and epigenetic inactivation of remaining allele of such a frequently methylated tumor suppressor gene exists in cholangiocarcinoma.
Previous genetic studies have shown that there are different profiles between intrahepatic and extrahepatic cholangiocarcinoma. For instance, Kang et al 3 found more frequent K-ras mutation, in cholangiocarcinoma arising in major bile ducts such as hilar cholangiocarcinoma, but only very rare mutations seen in peripheral type or intrahepatic cholangiocarcinoma. A recent immunohistochemical study also suggests that intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma have different cytokeratin immunoprofiles. 30 Intrahepatic cholangiocarcinoma tends to be CK7 þ /CK20À, while extrahepatic cholangiocarcinoma is more frequently CK7 þ /CK20 þ . 30 To further understand the epigenetic changes in cholangiocarcinoma, we have compared the methylation profiles and patterns between intrahepatic-and extrahepatic cholangiocarcinoma. We found that different methylation profiles do exist between intrahepaticand extrahepatic cholangiocarcinoma. Most of the tumor suppressor genes analyzed had similar methylation frequencies between intrahepatic-and extrahepatic cholangiocarcinoma, such as methylations of APC, E-cadherin/CDH1, p15
INK4b , p16
INK4a
and MGMT. However, methylation of RASSF1A and GSTP showed significant differences between intrahepatic-and extrahepatic cholangiocarcinoma. Methylation of RASSF1A was more frequently seen in extrahepatic cholangiocarcinoma than in intrahepatic cholangiocarcinoma (84 vs 47%), whereas methylation of GSTP was more commonly seen in intrahepatic cholangiocarcinoma (31 vs 6%). The high frequency of RASSF1A methylation closely resembles that seen in adenocarcinoma of the pancreas. 16 Whereas the higher frequency of GSTP methylation may be related to the close proximity between intrahepatic cholangiocarcinoma and hepatocellular carcinoma, which also harbors frequent methylation of GSTP promoter. 31 By dissecting the association between pairs of tumor suppressor gene methylation (Figure 2a and b) , we found that although six pairs of such associations (mainly with RASSF1A and APC) were observed both in intrahepatic-and extrahepatic cholangiocarcinoma, majority of the bivariate associations were different between intrahepatic-and extrahepatic cholangiocarcinoma. Our findings support the notion that intrahepatic-and extrahepatic cholangiocarcinoma may be two closely related but different biologic entities. Accurate diagnosis of cholangiocarcinoma in cytologic specimens, such as biliary brushing and fine-needle aspiration biopsy, is notoriously challenging for pathologists. One of the main reasons is that most cholangiocarcinomas have well-differentiated histopathologically and morphologically overlap with reactive biliary epithelia. As concurrent methylation of multiple tumor suppressor genes was not seen in benign biliary epithelium, methylationspecific PCR analysis of a set of tumor suppressor genes could be useful in facilitating accurate diagnosis of cholangiocarcinoma from benign/reactive biliary epithelium in preoperative biopsy or cytologic brushings. By analysis of a limited number of cytologic samples (biliary brushing and fineneedle aspiration and biopsy smears), we found that cytologic specimens (air-dried smears with DiffQuik stain or alcohol-fixed smears with Papanicolaou stain) yield equal or better methylation-specific PCR results compared to recuts from paraffinembedded tissues, probably due to less genomic fragmentation in cytologic specimens than formalinfixed surgical specimens. Besides its fast and less complicated technical merits, one of the advantages of methylation-specific PCR technique is that it can differentially detect hypermethylated allele (often seen in malignant cells) from unmethylated allele (often seen in normal cells) by designing different size of the PCR products. This is particularly useful for applying it in clinical materials since it does not require the enrichment of cancer cells from background reactive inflammatory cells and stromal cells. It should be noted that our comparison tissues were not normal bile ductal epithelia, but rather benign biliary epithelia of negative surgical margins that are far (42 cm) from cancerous lesions. In order to assess the utility of methylation profiling in diagnostic pathology, it is important to study the background benign tissue surrounding malignant lesions. Our data show that although single gene methylation can be seen in benign biliary epithelia, it is the concurrent multiple gene methylation profiling that may be clinically useful in distinguishing cholangiocarcinoma from benign biliary epithelium.
In summary, we found that promoter methylation of tumor suppressor genes was frequent in cholangiocarcinoma. Intrahepatic-and extrahepatic cholangiocarcinoma have overlapping but different methylation profiles. Concurrent methylation of multiple tumor suppressor genes is a unique finding in cholangiocarcinoma since it was not found in benign biliary epithelia. Such concurrent methylation patterns in cholangiocarcinoma may be a useful adjunctive diagnostic test for cholangiocarcinoma in clinical samples, such as cytologic or small biopsy specimens that are not uncommonly frequent with difficulty using morphologic features alone.
